Vanda Pharmaceuticals Inc.
NASDAQ:VNDABiotechnology
-$0.20 today
- Market cap
- $226.76M
- Beta
- 0.60
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$4.03
Volume 0.95M
Average 1.29M
VNDA Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Vanda Pharmaceuticals Inc.NASDAQ: VNDA
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $221K (cash outflow) fell 49.3% year over year, behind the -14.8% change in trailing-twelve-month capital expenditures. Sequentially, it rose 116.7% from the prior quarter. Over 3 fiscal years it compounded at +13.7% a year.
Context
- Capital expenditures amounted to 0.5% of revenue in FY2025, up 0.2 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -49.3% toward the trailing-twelve-month pace of -14.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (998K) USD
- Year-over-year change
- -103.7%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (998K) | -103.7% |
| FY2024 | 2024-12-31 | (490K) | -27.9% |
| FY2023 | 2023-12-31 | (383K) | +43.6% |
| FY2022 | 2022-12-31 | (679K) | -23.0% |
| FY2021 | 2021-12-31 | (552K) | — |
Capital Expenditures vs competitors
How VNDA compares with its peers on the latest reported figures
- VNDA's LTM Mar 2026 capital expenditures of $783K is the 4th largest of the 11 companies compared; the peer median is $254.6K.
- Its year-over-year change of -14.8% is the 5th highest of 8, against a peer median of -4.2%.
- Capital expenditures amounts to 0.4% of revenue for VNDA, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $21.33M | +958.6% | -4.7% | — | |
| LTM Mar 2026 | $1.95M | -4.2% | +1.4% | 5.3% | |
| LTM Mar 2026 | $831K | -41.0% | -5.5% | 41.2% | |
| LTM Mar 2026 | $783K | -14.8% | +13.7% | 0.4% | |
| LTM Mar 2026 | $318.66K | -41.5% | -69.0% | 0.7% | |
| LTM Mar 2026 | $296K | -62.3% | -57.9% | — | |
| LTM Mar 2026 | $213.21K | +278.4% | -42.4% | — | |
| LTM Mar 2026 | $59K | +101.7% | -28.8% | 1.0% | |
| LTM Mar 2026 | $3K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding VNDA) | $254.6K | -4.2% | -28.8% | 3.2% | |
Competitors are the stored peer set for VNDA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 33.15M | 6.28M | 2.51M | (18.9M) | (220.47M) |
| Depreciation & Amortization | 2.84M | 2.73M | 3.01M | 8.13M | (950K) |
| Deferred Income Tax | 6.75M | 1.13M | (1.29M) | (6.48M) | 81.44M |
| Stock-Based Compensation | 15.37M | 16.28M | 14.04M | 12.43M | 9.47M |
| Change in Working Capital | 2.74M | 6.07M | (747K) | (6.56M) | 8.31M |
| Accounts Receivables | (2.47M) | (1.09M) | (707K) | (13.01M) | (7.46M) |
| Inventory | (2.23M) | (4.48M) | (771K) | (29K) | (3.47M) |
| Accounts Payables | 3.04M | 11.79M | (10.98M) | 1.71M | 15.82M |
| Other Working Capital | 4.4M | (151K) | 11.72M | 4.78M | 3.42M |
| Other Non-Cash Items | 3.37M | (507K) | (4.73M) | (4.38M) | 12.76M |
| Operating Cash Flow | 64.21M | 31.98M | 12.8M | (15.76M) | (109.44M) |
| Capital Expenditures | (552K) | (679K) | (383K) | (490K) | (998K) |
| Acquisitions (Net) | 0 | 0 | (100.67M) | (4.23M) | 0 |
| Purchases of Investments | (420.46M) | (349.26M) | (512.61M) | (364.77M) | (112.38M) |
| Sales of Investments | 344.32M | 399.86M | 601.6M | 352.06M | 208.24M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (76.7M) | 49.93M | (12.06M) | (17.43M) | 94.86M |
| Debt Repayment | 0 | 0 | 0 | (155K) | (1.99M) |
| Common Stock Issued | 3.55M | 734K | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | (915K) |
| Financing Cash Flow | 3.55M | 734K | 0 | (155K) | (2.91M) |
| Effect of Forex Changes | (85K) | 315K | 47K | (163K) | 126K |
| Net Change in Cash | (9.02M) | 82.96M | 792K | (33.51M) | (17.36M) |
| Free Cash Flow | 63.66M | 31.31M | 12.42M | (16.25M) | (110.44M) |
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
Intrinsic Alpha fair value
Locked
Current Price
$3.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.